Sandoz Expects Imminent US Pegfilgrastim Action

Seven Months Have Passed Since Refiling With FDA

 
• By Aidan Fry
  
Approved_Stamp
Sandoz is eagerly awaiting FDA clearance for its pegfilgrastim biosimilar candidate • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products